Squalene epoxidase promotes hepatocellular carcinoma development by activating STRAP transcription and TGF‐β/SMAD signaling
Zhirui Zhang,Wei Wu,Hao Jiao,Yuzhong Chen,Xiaojun Ji,Jing Cao,Fangzhou Yin,Wu Yin
DOI: https://doi.org/10.1111/bph.16024
IF: 7.3
2022-12-31
British Journal of Pharmacology
Abstract:Background and Purpose Squalene epoxidase (SQLE) is a key enzyme involved in cholesterol biosynthesis, but increasing evidence reveals that SQLE is abnormally expressed in some types of malignant tumors, and the underlying mechanism remains poorly understood. Experimental Approach Bioinformatics analysis and RNA sequencing were applied to detect to differentially expressed genes in clinical hepatocellular carcinoma (HCC). MTT, colony formation, AnnexinV‐FITC/PI, EdU, wound healing, transwell, western blot, qRT‐PCR, IHC, F‐actin, RNA‐sequencing, dual‐luciferase reporters and HE staining were evaluated to investigate the pharmacological effects and possible mechanisms of SQLE. Key Results SQLE expression was specifically elevated in HCC, correlating with poor clinical outcomes. SQLE significantly promoted HCC growth, epithelial‐mesenchymal transition, and metastasis both in vitro and in vivo. Both RNA‐seq and functional experiments revealed that the protumorigenic effect of SQLE on HCC is closely related to the activation of TGF‐β/SMAD signaling, but interestingly, the stimulatory effect of SQLE on TGF‐β/SMAD signaling and HCC development is critically dependent on STRAP. SQLE expression is well correlated with STRAP in HCC, and further, to amplify TGF‐β/SMAD signaling, SQLE even transcriptionally increased STRAP gene expression mediated by AP‐2α. Finally, as a chemical inhibitor of SQLE, NB‐598 markedly inhibited HCC cell growth and tumor development. Conclusions and Implications Taken together, SQLE serves as a novel oncogene in HCC development by activating TGF‐β/SMAD signaling, and targeting SQLE could be useful in drug development and therapy for HCC.
pharmacology & pharmacy